BamSEC and AlphaSense Join Forces
Learn More

Ikena Oncology Inc.

NASDAQ: IKNA    
Share price (12/23/24): $1.67    
Market cap (12/23/24): $80.6 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.7
from 8-K 42 pages Subscription Agreement
12/34/56
EX-10.6
from 8-K 5 pages Lock-Up Agreement
12/34/56
EX-10.5
from 8-K 13 pages Ikena Oncology, Inc. Support Agreement
12/34/56
EX-10.4
from 8-K 13 pages Inmagene Biopharmaceuticals Support Agreement
12/34/56
EX-10.2
from 8-K 19 pages Form of Company Contingent Value Rights Agreement
12/34/56
EX-10.1
from 8-K 20 pages Form of Insight Contingent Value Rights Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Info@ikenaoncology.com | 645 Summer St. Suite 101 Boston, Ma 02210 | WWW.IKENAONCOLOGY.com
12/34/56
EX-10.1
from 10-Q 2 pages Info@ikenaoncology.com | 645 Summer St. Suite 101 Boston, Ma 02210 | WWW.IKENAONCOLOGY.com
12/34/56
EX-10.1
from 8-K 10 pages Ikena Oncology, Inc. Consulting Agreement
12/34/56
EX-10.1
from 8-K 25 pages Contingent Value Rights Agreement
12/34/56
EX-10
from 10-K 3 pages Ikena Oncology, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.6
from S-1/A 16 pages Employment Agreement
12/34/56
EX-10.5
from S-1/A 34 pages Ikena Oncology, Inc. Form of Director Indemnification Agreement
12/34/56
EX-10.4
from S-1/A 2 pages Ikena Oncology, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.3
from S-1/A 7 pages Ikena Oncology, Inc. 2021 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 39 pages Ikena Oncology, Inc. 2021 Stock Option and Incentive Plan
12/34/56
EX-10.10
from S-1 74 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. 645 Summer Street Boston, Ma Lease Agreement Between Opg Mp Parcel Owner (De) LLC, a Delaware Limited Liability Company, as Landlord and Ikena Oncology, Inc., a Delaware Corporation, as Tenant Lease Agreement
12/34/56
EX-10.9
from S-1 41 pages Background
12/34/56
EX-10.8
from S-1 80 pages Master Collaboration Agreement by and Between Celgene Corporation and Kyn Therapeutics Inc. Dated as of January 11, 2019
12/34/56
EX-10.7
from S-1 56 pages License Agreement
12/34/56